Drug delivery of poorly soluble drugs in form amorphous solid dispersions (ASDs) is an
appealing method to increase in vivo bioavailability. For rational formulation design, a …

Amorphous solid dispersions (ASDs) can increase the oral bioavailability of poorly soluble
drugs. However, their use in drug development is comparably rare due to a lack of basic …

The tendency of highly supersaturated solutions of poorly water-soluble drugs to undergo
liquid–liquid phase separation (LLPS) into drug-rich and water-rich phases when the …

To reduce the dosage size of amorphous solid dispersion (ASD)-based formulations, it is of
interest to devise formulation strategies that allow increased drug loading (DL) without …

Purpose To understand how surfactants affect drug release from ternary amorphous solid
dispersions (ASDs), and to investigate different mechanisms of release enhancement …

Formulating poorly soluble molecules as amorphous solid dispersions (ASDs) is an effective
strategy to improve drug release. However, drug release rate and extent tend to rapidly …

Two widely applied enabling drug delivery approaches, self-nanoemulsifying drug delivery
systems (SNEDDS) and amorphous solid dispersions (ASD), were combined, with the aim of …

The development of amorphous solid dispersions (ASDs) is one way to overcome the
bioavailability challenges of poorly water-soluble active pharmaceutical ingredients (APIs) …

The delivery of poorly water-soluble drugs using amorphous solid dispersions (ASDs) has
been widely acknowledged as a promising strategy for enhancing oral bioavailability. Upon …

Enzalutamide is a fast crystallizing, hydrophobic compound that has solubility limited
absorption in vivo. Given the low aqueous solubility of this compound, it was of interest to …